

Supplementary Material

Relationship between dietary FA intake with NAFLD and/or liver fibrosis in people with HIV mono-infection

Supplementary Table S1. Clinical and demographic characteristics of participants with HIV mono-infection and non-alcoholic fatty liver disease (NAFLD) [CAP \geq 248 dB/m; n=152, prevalence= 37%] included in the analysis in INI/FIOCRUZ. Rio de Janeiro, Brazil

		NAFLD (n=152)
Social and demographic		
Female sex ^a		87 (57.2)
Age, years ^b		50 (41 - 55)
Self-reported skin color ^a		
	White	82 (53.9)
	Brown	42 (27.6)
	Black	27 (17.8)
	Others	1 (0.7)
Education ^a <8 years of study		74 (48.7)
Biochemistry		
ALT, IU/L ^b		34 (25 - 50)
AST, IU/L ^b		25 (20 - 34)
Alkaline phosphatase, IU/L ^b		87 (68 - 110)
GGT, IU/L ^b		51 (37 - 85)
Total cholesterol, mg/dL ^b		196 (171 - 222)
LDL - cholesterol, mg/dL ^b		116 (91 - 142)
HDL - cholesterol, mg/dL ^b		41 (33 - 50)
Triglycerides, mg/dL ^b		165 (112 - 243)
Fasting glucose, mg/dL ^b		98 (89 - 106)
Insulin, um/L		15 (10 - 20)
HOMA-IR		4 (2 - 5)
Nutritional Status		
BMI(kg/m ²) ^b		29 (26 - 32)
BMI(kg/m ²) ^a		
	Lean [< 25 Kg/m ²] ^a	27 (17.8)
	Overweight [25 – 29,99 Kg/m ²] ^a	65 (42.8)
	Obesity [≥ 30 Kg/m ²] ^a	60 (39.5)
Body fat, (%) by bioimpedance ^b		32 (27 - 37)
Comorbidities		
Diabetes mellitus ^a		34 (22.4)
Hypertension ^a		52 (34.2)
Dyslipidaemia ^a		44 (28.9)
Metabolic syndrome ^a		87 (58.8)
HIV infection and ART		
Duration of HIV, years ^b		12 (7 - 19)
CD4+ T-lymfocyte count (cells/m ³) ^b		708 (524 - 935)
Current ART use ^a		147 (96.7)

Duration of ART, years^b

10 (4 - 16)

Data expressed as n (%) ^a or median (IQR) ^b. ALT, alanine transaminase; ART, antiretroviral therapy; AST, aspartate transaminase; BMI, body mass index; GGT, gamma-glutamyltransferase, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease.

Supplementary Table S2 Clinical and demographic characteristics of participants with HIV mono-infection and significant liver fibrosis (stage F≥2) [LSM ≥ 7.1 kPa or ≥ 6.2 kPa with M or XL probe; n=72, prevalence= 16%] included in the analysis in INI/FIOCRUZ. Rio de Janeiro, Brazil

		Liver fibrosis n=72
Social and demographic		
Female sex ^a		42 (58.3)
Age, years ^b		47 (41 - 54)
Self-reported skin color ^a		
	White	33 (45.8)
	Brown	20 (27.8)
	Black	18 (25)
	Outros	1 (1.4)
Education ^a <8 years of study		37 (51.4)
Biochemistry		
ALT, IU/L ^b		36 (25 - 56)
AST, IU/L ^b		29 (22 - 41)
Alkaline phosphatase, IU/L ^b		86 (68 - 108)
GGT, IU/L ^b		54 (36 - 111)
Total cholesterol, mg/dL ^b		176 (153 - 203)
LDL - cholesterol, mg/dL ^b		102 (83 - 125)
HDL - cholesterol, mg/dL ^b		42 (35 - 52)
Triglycerides, mg/dL ^b		140 (80 - 187)
Fasting glucose, mg/dL ^b		95 (90 - 103)
Insulin, um/L		12 (7 - 20)
Homa-IR		3 (2 - 5)
Nutritional Status		
BMI(kg/m ²) ^b		29 (24 - 33)
BMI(kg/m ²) ^a		
	Lean [< 25 Kg/m ²] ^a	25 (34.7)
	Overweight [25 – 29,99 Kg/m ²] ^a	18 (25)
	Obesity [≥ 30 Kg/m ²] ^a	29 (40.3)
Body fat, (%) by bioimpedance ^b		32 (24 - 38)
waist circumference (cm)		91 (82 - 104)
Comorbidities		
Diabetes mellitus ^a		16 (22.2)
Hypertension ^a		29 (40.3)
Dyslipidaemia ^a		17 (23.6)
Metabolic syndrome ^a		32 (45.1)
HIV infection and ART		
Duration of HIV, years ^b		11 (4 - 16)
CD4+ T-lymfocyte count (cells/m ³) ^b		648 (361 - 842)
CD4+ T-lymfocyte count (<200cells/m ³) ^a		5 (7.1)
Current ART use ^a		68 (94.4)
Duration of ART, years ^b		10 (3 - 15)

Data expressed as n (%) ^a or median (IQR) ^b. ALT, alanine transaminase; ART, antiretroviral therapy; AST, aspartate transaminase; BMI, body mass index; GGT, gamma-glutamyltransferase, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease.